Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma

Authors not listed

Guangdong Provincial People's Hospital · 2020

Abstract

About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2020). Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma. <em>Guangdong Provincial People's Hospital</em>. https://clinicaltrials.gov/study/NCT04622579
Vancouver
Anonymous. Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma. Guangdong Provincial People's Hospital. 2020.
BibTeX
@misc{anon2020Lenali, title = {Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma}, author = {Anonymous}, journal = {Guangdong Provincial People's Hospital}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings